通过p53-Reprimo-Hippo-YAP/TAZ-p73途径引发亡和瘤抑制的外部诱导
Masahiro Takikawa1,2, Airi Nakano1,3, Jayaraman Krishnaraj1
1Laboratory of Fundamental Oncology, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan.
瘤抑制基因p53准RPRM,其蛋白质产物Reprimo被分泌以诱导癌细胞的亡. 这一发现揭示了一个新的外部亡途径,对于瘤抑制和潜在的癌症疗法至关重要.
科学领域:
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
- 癌症研究 癌症研究
背景情况:
- 瘤的进展是由细胞机制,如亡抑制.
- 在人类癌症中,p53瘤抑制基因经常发生突变.
- RPRM是一种p53点基因,涉及瘤抑制,但其功能尚不清楚.
研究的目的:
- 阐明Reprimo (RPRM) 的分子功能.
- 确定Reprimo抑制瘤进展的机制.
- 研究Reprimo作为癌症治疗点的潜力.
主要方法:
- 研究了Reprimo的分泌和亡功能.
- 鉴定出原cadherin家族成员 (FAT1,FAT4,CELSR1-3) 作为Reprimo受体.
- 分析了Reprimo在Hippo-YAP/TAZ-p73信号通路中的作用.
主要成果:
- 雷普里莫被分泌,并诱导受体细胞中的外部亡.
- 雷普里莫与原卡德林受体结合,激活Hippo-YAP/TAZ-p73轴.
- 雷普里莫可通过激活前性基因,抑制瘤生长 in vivo.
结论:
- 确定了一个新的外部亡途径:p53-Reprimo-Hippo-YAP/TAZ-p73.
- 雷普里莫作为一种先天的瘤消除剂.
- 雷普里莫疗法为癌症药物治疗提供了一个有希望的目标.
更多相关视频
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
07:16Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
相关概念视频
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
The Extrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
